Contribution of Renal and Non‐Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease
- 29 June 2013
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 53 (9) , 919-924
Abstract
The contribution of renal and non‐renal clearance toward targeted concentrations and/or effects of therapeutic proteins in nephrotic patients are unknown. This study dissected the contribution of clearance pathways to adalimumab elimination in patients with focal segmental glomerulosclerosis (FSGS). Urine was collected from seven patients treated with adalimumab. Renal clearance (ClR) was measured and non‐renal clearance (ClNR) was calculated as the difference between total clearance and ClR. Differences in cumulative amount in urine, ClR, and ClNR between study weeks 1 and 16 and relationships between proteinuria (protein:creatinine ratio (Up/c)), and ClR and ClNR were evaluated. Up to 13% of the adalimumab dose was lost in urine. ClNR contributed more than ClR to enhanced total clearance. There was a nonlinear relationship between Up/c and ClR (R2 0.7059); an increase in ClR beginning at Up/c of 12 mg/mg [slope 1.755, (C.I. −7.825 to 11.34)]. There was a linear relationship between Up/c and ClNR (R2 0.5039); for every one unit increase in Up/c, ClNR would increase by 3.5 mL/hr (P = 0.01). Both ClR and ClNR contribute to enhanced total clearance of adalimumab in glomerular disease secondary to FSGS. Additional research is needed to identify mechanisms for the increased ClNR pathways.Keywords
This publication has 24 references indexed in Scilit:
- Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic SyndromeClinical Journal of the American Society of Nephrology, 2011
- Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study designBMC Nephrology, 2011
- Rituximab Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study GroupAmerican Journal of Kidney Diseases, 2010
- A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patientsArthritis Care & Research, 2009
- Effects of Rituximab on Morphofunctional Abnormalities of Membranous GlomerulopathyClinical Journal of the American Society of Nephrology, 2008
- Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusExpert Opinion on Drug Safety, 2008
- Podocytes use FcRn to clear IgG from the glomerular basement membraneProceedings of the National Academy of Sciences, 2008
- Rituximab treatment of idiopathic membranous nephropathyKidney International, 2008